Originally published: (2010) 3M Corporation
3M and Tegaderm are trademarks of 3M. Used under license in Canada. © 2010, 3M. All rights reserved. 1006-01874E
Download PDF

Authors:

Joanne Knudsen, RN, (CMA)
Wilma Sterling, RN, CRRN, IIWCC
Donnie McIntosh, MEd, BN, RN
Olen de Lemos Yee, BSN, RN
Heather Nelson, RN
Shirley Clow, RN, IIWCC
Tricia Hoeppner, BScPT
Susan Mills- Zorzes, RN, BScN, MDE, CWOCN

Summary:

This document presents eight case studies evaluating the clinical performance of 3M™ Tegaderm™ Matrix Dressing in treating non-healing chronic wounds that had not responded to other therapies.

Key findings from the case studies include:

• Case Study 1: A 56-year-old male with a recurrent subkeratotic hematoma on an amputation site, stalled for 2.5 years, showed significant improvement and near closure after 8 weeks of treatment.
• Case Study 2: A 57-year-old male with two toe wounds (burn and amputation site) stalled for 2-3 months, achieved closure for both wounds after 6 weeks.
• Case Study 3: A 96-year-old female with a Stage III pressure ulcer on her heel, stalled for 10 months, showed noticeable improvement in 2 weeks and closure after 9 weeks, with reported pain reduction.
• Case Study 4: A 95-year-old female with a skin tear with hypergranulation tissue, stalled for 2 months, saw resolution of hypergranulation in 7 days and near closure in 18 days.
• Case Study 5: An 81-year-old female with two pressure ulcers on her coccyx, stalled for 3 months, had the smaller wound close completely and the larger wound reduce by 87% in 20 days.
• Case Study 6: A 68-year-old male with a small, painful ulcer of mixed vascular etiology, present for 10 months, showed near closure in 48 hours and complete closure after one week.
• Case Study 7: A 101-year-old female with a Stage III pressure ulcer on her heel, stalled for 4 months, achieved significant reduction in size after 6 weeks and complete closure after 9 weeks.
• Case Study 8: A 71-year-old female with an arterial ulcer on her lower leg, stalled for 16 months and with poor circulation, experienced a 95% reduction in wound size over 15 weeks.

The 3M™ Tegaderm™ Matrix Dressing utilizes a polyhydrated ionogen (PHI) ointment containing metal ions (rubidium, potassium, zinc, calcium) and citric acid. This technology aims to regulate gene expression for matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), normalize wound pH, and reduce reactive oxygen species (ROS) activity, thereby promoting healing in chronic wounds. The authors conclude that 3M™ Tegaderm™ Matrix should be considered a first-line treatment for non-healing chronic wounds.